個股熱度排行 | 4月14日港股盤前
根據uSMART輿情監測數據，從13日晚間到14日港股盤前時間段，市場關注指數最高的5只股票是復星醫藥、金風科技、第一拖拉機股份、麗珠醫藥、歌禮制藥-B。
4月14日—港股關注排行TOP5
復星醫藥
關注度第一爲復星醫藥，該股上個交易日收盤下跌5.18%，報於32.95港元。近5個交易日累計下跌18.64%。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
復星醫藥控股子公司新冠抗原檢測試劑盒獲批上市 ；金風科技擬188億元投建溫州海上風電產業基地等項目
復星醫藥：復星診斷新冠抗原檢測試劑盒獲批上市
金風科技
關注度第二爲金風科技，該股上個交易日收盤上漲1.21%，報於11.70港元。近5個交易日累計上漲2.09%。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
金風科技：擬投建溫州海上風電產業基地 公司及引入其他企業投資共計約188億元
復星醫藥控股子公司新冠抗原檢測試劑盒獲批上市 ；金風科技擬188億元投建溫州海上風電產業基地等項目
第一拖拉機股份
關注度第三爲第一拖拉機股份，該股上個交易日收盤下跌1.45%，報於4.08港元。近5個交易日累計持平。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
第一拖拉機股份：劉繼國獲選爲董事長
第一拖拉機股份4月27日董事會審議及批準一季度業績
麗珠醫藥
關注度第四爲麗珠醫藥，該股上個交易日收盤下跌0.95%，報於26.00港元。近5個交易日累計下跌8.29%。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
復星醫藥、麗珠醫藥子公司新冠抗原檢測試劑盒獲批上市 中國平安首季保費收入達2464.77億元
麗珠醫藥：麗珠試劑新型冠狀病毒抗原檢測試劑獲醫療器械註冊證
歌禮制藥-B
關注度第五爲歌禮制藥-B，該股上個交易日收盤下跌0.42%，報於4.78港元。近5個交易日累計下跌17.01%。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
歌禮制藥-B：中國醫藥保健品有限公司成爲利託那韋片在中國大陸地區的經銷商
歌禮制藥與中國醫藥簽訂經銷商協議
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
